[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,620,0,25,[9,45,72,100,121,146,167,187,208,230,253,269,288,309,327,345,363,380,406,426,466,484,505,524,547],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100631466","phase-1-a-phase-1-study-of-blkr201-in-healthy-adult-participants-100631466",false,"NCT07501039","A Phase 1 Study of BLKR201 in Healthy Adult Participants","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BLKR201 in Healthy Adult Participants","Inclusion Criteria:\n\n* Are a healthy man or woman 18 to 55 years old\n* Weigh at least 50 kilograms (110 pounds)\n* Have a body mass index (BMI) between 18 and 30 kg\u002Fm2 (inclusive)\n* Are willing to stay at the research unit for the required study visits\n* Are willing to follow study rules about diet, alcohol, tobacco, and medications\n* Are able to understand and sign the informed consent form\n\nWomen who can become pregnant must:\n\n* Have a negative pregnancy test before starting\n* Use a highly effective form of birth control during the study and for a period after the last dose\n\nMen with partners who can become pregnant must:\n\n* Use highly effective birth control during the study and for a period after the last dose\n* Not donate sperm during that time\n\nExclusion Criteria:\n\n* Have any significant medical condition involving the heart, lungs, liver, kidneys, stomach, intestines, brain, blood, or immune system\n* Have abnormal laboratory test results at screening that the study doctor considers important\n* Have a history of heart rhythm problems or abnormal electrocardiogram (ECG) results\n* Have high blood pressure at screening\n* Have had a serious infection within the past 6 months\n* Test positive for HIV, hepatitis B, hepatitis C, or tuberculosis, or show evidence of hepatitis B infection (positive hepatitis B surface antigen or hepatitis B core antibody). Note: participants with hepatitis B immunity from vaccination alone may still be eligible.\n* Have a history of cancer in the past 5 years (with limited exceptions for certain treated skin cancers)\n* Have a history of serious stomach problems such as ulcers, stomach surgery, or stomach bleeding\n* Use tobacco, nicotine, or marijuana products\n* Test positive for drugs or alcohol at screening\n* Have taken another investigational drug within the required time before this study\n* Have received a live vaccine within 30 days before study start\n* Are pregnant or breastfeeding\n* Have a known allergy to the study drug or similar medicines\n\nAdditional exclusions:\n\n* Regular heavy alcohol use\n* Regular use of certain medications such as anti-inflammatory drugs, steroids, or blood thinners\n* Donation of more than 500 milliliters (about one pint) of blood within 1 month before screening\n\nFor the spinal fluid (CSF) portion of the study, you cannot take part if you:\n\n* Take blood-thinning medications\n* Have bleeding or clotting problems\n* Have sensitivity to lidocaine, band aids, adhesive dressing, or medical tape\n* Have medical conditions that make a spinal tap unsafe",true,"ALL","18 Years","55 Years",{"count":22,"type":23},128,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","The goal of this clinical trial is to learn if BLKR201 is safe in healthy adults. Researchers will also learn how the body absorbs and processes BLKR201 and how food may affect it.\n\nThe main questions this study aims to answer are:\n\n* Is BLKR201 safe and well tolerated when taken as a single dose or for several days in a row?\n* How does BLKR201 move through and leave the body?\n* Does taking BLKR201 with food change how the body absorbs it?\n\nResearchers will compare BLKR201 to a placebo (a look-alike tablet that contains no drug) in most parts of the study to see how the drug affects participants.\n\nParticipants will:\n\n* Take BLKR201 or a placebo by mouth\n* Stay at a clinical research unit for several days during dosing\n* Give blood and urine samples\n* Have heart tests, vital signs, and lab tests\n* Report any side effects\n\nIn one part of the study, a small group of participants will receive BLKR201 only (no placebo). These participants will also have a sample of spinal fluid collected to measure how much BLKR201 reaches the fluid around the brain and spinal cord.",[29],"Healthy",[29,31],"Healthy Volunteers","RECRUITING","2026-08-20",{"date":35,"type":36},"2026-08-21","ACTUAL",{"date":38,"type":36},"2026-04-27",{"date":40,"type":23},"2027-02",{"name":42,"class":43},"Formation Bio, Inc.","INDUSTRY",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":17,"sex":18,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":56,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100605983","pet-imaging-of-phosphodiesterase-4-pde4-in-volunteers-with-alzheimer-disease-ad-or-mild-cognitive-impairment-mci-100605983","NCT07169630","PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)","PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer s Disease (AD) or Mild Cognitive Impairment (MCI)","* INCLUSION CRITERIA:\n\nParticipants will be referred by a physician with the suspected diagnosis of AD or MCI. However, the PI of this protocol will provide the final diagnosis. For this reason, this protocol will have just one consent form for participants suspected of having either AD or MCI.\n\nAD and MCI Study Groups:\n\nParticipants must meet all the following criteria:\n\n* Aged 50 or older.\n* Be able (or have their Legally Authorized Representative (LAR) be able) to understand the study and be willing to sign a written informed consent document.\n* Have been diagnosed by a neurologist or psychiatrist with MCI or AD.\n* Be in good general health as evidenced by medical history and physical examination.\n* Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n* Agree to adhere to the lifestyle considerations.\n\nHealthy Volunteers:\n\nParticipants must meet all the following criteria:\n\n* Aged 50 or older.\n* Able to provide informed consent.\n* Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment.\n* Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n* Agree to adhere to the lifestyle considerations.\n\nEXCLUSION CRITERIA:\n\nBoth the study groups will be excluded if they meet any of the following criteria:\n\n* Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen).\n* Participants should not have taken non-steroidal anti-inflammatory drugs (NSAIDs) for two weeks prior to the PET scan. Aspirin, corticosteroids (with the exception of skin products), or immunosuppressants (e.g., methotrexate) must not have been taken in the prior month.\n* Have other major neurological or medical diseases that may cause cognitive dysfunction, such as structural brain diseases, metabolic diseases, paraneoplastic syndromes, infectious diseases, or other significant neurological abnormalities.\n* Have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy).\n* Are unable to travel to the NIH.\n* Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits.\n* Have an inability to lie flat and\u002For lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the volunteer and\u002For caregiver during the screening visit.\n* Participants must not have substance use disorder or alcohol use disorder.\n* Participants should not be under treatment or previously treated with an amyloid antibody such as lecanemab.\n* Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye).\n* Pregnancy or breast feeding.\n* HIV infection.\n* Non-English speaking participants.\n\nExclusion of Children:\n\nInclusion of children is not appropriate, because this protocol has more than minimal risk from radiation exposure without the possibility of direct benefit.\n\nExclusion of Pregnant or Breastfeeding Women:\n\nPregnant women will be excluded because this protocol involves exposure to ionizing radiation. Lactating women will be excluded because radioisotopes may be excreted in milk. We will not require contraception for this protocol to allow participants autonomy in medical decision-making. However, while we will not require contraception for woman of childbearing potential, we will perform a pregnancy test at screening and prior to all procedures to ensure participants are not pregnant\n\nExclusion of Participants who are HIV Positive:\n\nPersons with HIV infection are excluded because HIV infection itself may change cAMP signaling.\n\nExclusion of Non-English-Speaking Participants:\n\nNon-English-speaking participants will be excluded from participation in this study because neuropsychological testing is required by this protocol. This testing, which is critical for interpreting study results, has not been validated in other languages or when using a translator.","50 Years","100 Years",{"count":55,"type":23},90,[26],"Background:\n\nAbout 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias. The number of people with these disorders will likely increase as the population ages and life span increases. Inflammation is thought to play a role in AD and MCI. Researchers want to know if an enzyme called PDE4B increases inflammation in people with AD or MCI.\n\nObjective:\n\nTo test whether medical imaging using a new radiotracer (\\[18F\\]PF-06445974) can measure PDE4B in the brains of people with AD or MCI.\n\nEligibility:\n\nPeople aged 50 years and older with AD or MCI. Healthy volunteers are also needed.\n\nDesign:\n\nParticipants will have up to 5 clinic visits with 3 imaging scans of the brain.\n\nThey will have be screened. They will have a physical exam with blood tests. This will include tests of their heart and nerve function, including memory.\n\nParticipants will have 2 positron emission tomography (PET) scans. One will use a standard radiotracer. The other will use the study radiotracer. They will receive each tracer through a tube attached to a needle inserted into a vein. During the scan with the study tracer, participants will have a second tube inserted into a vein in the wrist; this tube will be used to draw blood during the scan. Participants will lie on a bed that slides into a doughnut-shaped machine. These visits will take about 6 hours each.\n\nParticipants will have 1 magnetic resonance imaging (MRI) scan. They will lie on a bed that slides into a cylinder. This visit will take up to 2 hours....",[59,60,29],"Alzheimer s Disease","Mild Cognitive Impairment",[62,63],"18F-PF-06445974","PET Imaging",{"date":35,"type":36},{"date":66,"type":23},"2026-08-26",{"date":68,"type":23},"2030-04-11",{"name":70,"class":71},"National Institute of Mental Health (NIMH)","NIH",{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":24,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":44},"100652595","dns-face-to-face-and-telerehabilitation-100652595","NCT07775560","DNS: Face-to-face and Telerehabilitation","Dynamic Neuromuscular Stabilization Exercises: A Comparative Study of Their Effectiveness Via Face-to-Face and Telerehabilitation Delivery","Inclusion Criteria:\n\n* Aged between 18 and 35 years.\n* Not engaged in regular physical activity within the past 6 months.\n* No history of musculoskeletal disorders or chronic diseases.\n* Able to participate consistently in the exercise program.\n\nFor the Tele-DNS (TDNS) group: access to reliable internet and appropriate technical equipment for the duration of the intervention.\n\nExclusion Criteria:\n\n* Diagnosis or history of neurological, cardiovascular, respiratory, or metabolic diseases.\n* History of spinal or extremity surgery.\n* Pregnancy.\n* Presence of postural deformities or any orthopedic conditions that may affect balance.","35 Years",{"count":81,"type":23},34,[83],"NA","This study aims to compare the effects of Dynamic Neuromuscular Stabilization (DNS) exercises delivered face-to-face (YDNS) and via tele-rehabilitation (TDNS) on respiratory function, balance, posture, core endurance, and deep stabilization system performance in healthy adults. A total of 34 participants will be randomly assigned to YDNS or TDNS groups and complete an identical 6-week DNS exercise program (3 sessions per week). Assessments will be conducted at baseline and post-intervention, including pulmonary function, Y-Balance Test, posture analysis, McGill's core stability tests, deep stabilization assessment, and patient satisfaction. All evaluations will be performed face-to-face by certified physiotherapists.",[29],[87,88,89,90],"core stabilization","balance","posture","respiratory parameters","2026-08-19",{"date":33,"type":36},{"date":94,"type":36},"2026-03-30",{"date":96,"type":23},"2026-12-30",{"name":98,"class":99},"Istinye University","OTHER",{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":24,"phases":110,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":117,"leadSponsor":119,"locationsCount":44},"100632005","high-resolution-pharyngeal-manometry-hrpm-biofeedback-100632005","NCT07508059","High Resolution Pharyngeal Manometry (HRPM) Biofeedback","Assessing the Impact of Biofeedback on Task Performance With Swallowing Maneuvers in Healthy Young Adults Using High Resolution Pharyngeal Manometry (HRPM)","Inclusion Criteria:\n\n1. Participants must be independent community dwelling adults.\n2. Participants must be between the ages of 18-40 years old.\n3. Willingness to consent and participate in the study procedures.\n4. No reported dysphagia or difficulty swallowing evidenced by an EAT-10 Score \\\u003C3.\n\nExclusion Criteria:\n\n1. Known structural or neurological causes of dysphagia (e.g., stroke, brain injury, or head\u002Fneck cancer).\n2. Recent or remote history of swallowing therapy; familiarity with swallowing maneuvers from relevant coursework as applicable (i.e., speech language pathology students).","40 Years",{"count":109,"type":23},50,[83],"The purpose of this study is to quantify the added benefit of visual biofeedback from High Resolution Pharyngeal Manometry (HRPM) for swallowing rehabilitation. Primary aims including assessing changes in swallowing biomechanics (pressure generation, timing) during swallow maneuvers with and without HRPM visual biofeedback. Secondary aim includes participant attitudes related to visual biofeedback and the experience of HRPM.",[29],[114],"Swallow",{"date":35,"type":36},{"date":91,"type":36},{"date":118,"type":23},"2027-05-01",{"name":120,"class":99},"NYU Langone Health",{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":17,"sex":18,"minAge":128,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":24,"phases":132,"briefSummary":134,"conditions":135,"keywords":136,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":145},"100605263","phase-3-beatrix-a-study-to-learn-about-a-group-b-streptococcus-vaccine-in-healthy-pregnant-women-and-their-babies-100605263","NCT07160244","BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies","A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY PREGNANT WOMEN AND THEIR INFANTS","Key Inclusion criteria- Maternal:\n\n* Healthy pregnant women ≤49 years of age who are between 24 0\u002F7 and 36 0\u002F7 weeks of gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, and who have no known increased risk of complications.\n* Had a fetal anomaly ultrasound examination with no significant fetal abnormalities observed.\n* Documented negative human immunodeficiency virus (HIV) antibody test, syphilis test, and hepatitis B virus (HBV) surface antigen test during this pregnancy and prior to randomization.\n* Capable of giving personal signed informed consent.\n* Willing to give informed consent for her infant to participate in the study.\n\nKey Exclusion criteria- Maternal:\n\n* Prepregnancy body mass index (BMI) of \\>40 kg\u002Fm2.\n* Current pregnancy complications or abnormalities that may increase the risk associated with the participation in and completion of the study.\n* Prior pregnancy complications or abnormalities that, based on the investigator's judgment, may increase the risk associated with the participation in and completion of the study.\n* History of microbiologically proven invasive disease caused by GBS in the current pregnancy.\n* A known or suspected infection during the current pregnancy that may increase the risk of complications in pregnancy (eg, active tuberculosis, syphilis, primary genital herpes simplex, malaria).\n\nKey Inclusion criteria- Infant Participants\n\n\\- Evidence of a signed and dated ICD signed by the parent(s)\u002Flegally authorized representative or legal guardian\n\nKey Exclusion Criteria - Infant Participants:\n\n\\- Children or grandchildren who are direct descendants of investigator site staff or sponsor and sponsor delegate employees directly involved in the conduct of the study.\n\nKey Exclusion Criteria - Infant immunogenicity subset Participants:\n\n\\- Children with a known or suspected contraindication to any vaccine administered in the infant vaccine immunogenicity subset.\n\nRefer to the study contact for further eligibility details","1 Day","49 Years",{"count":131,"type":23},6000,[133],"PHASE3","BEATRIX (group B strEptococcus mATeRnal and Infant VaX study) The purpose of this study is to learn about the safety and how the group B streptococcus (GBS) vaccine works in pregnant women and their babies.\n\nThis study is seeking healthy pregnant participants:\n\n* aged 49 or younger who can join.\n* between 24 and 36 weeks of gestation (\"Gestational age\" is a medical term used to describe how far along your pregnancy is)\n* had a fetal ultrasound examination performed with no major fetal abnormalities observed\n* documented negative for HIV, syphilis and Hepatitis B All participants in this study will receive only 1 shot in an arm. This could either be a group B streptococcus 6-valent polysaccharide conjugate vaccine (GBS6) or placebo. Placebo is an inactive substance used in the study for comparison purposes; in this study, the placebo injection will be saline (saltwater). The pregnant participants may take part in this study for a maximum of 14 months (6 months after delivery) , and their babies for about 12 months after they are born. The pregnant participants will need to visit the research site at least 3 to 4 times with some visits permitted to occur over the telephone.\n\nA subset of infants will be asked to take part in the study for up to 19 months. The subset will receive diphtheria toxoid-containing vaccine and\u002For pneumococcal vaccine following each country's standard immunization plan and have blood drawn 1 month after completion of the primary and\u002For toddler (booster) doses.",[29],[137],"group B streptococcus, maternal immunization, vaccine",{"date":33,"type":36},{"date":140,"type":36},"2025-08-25",{"date":142,"type":23},"2029-03-02",{"name":144,"class":43},"Pfizer",212,{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":52,"enrollmentInfo":153,"targetDuration":4,"studyType":24,"phases":155,"briefSummary":156,"conditions":157,"keywords":158,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":44},"100560453","phase-1-phase-1-single-ascending-doses-sad-of-m5542-in-healthy-participants-100560453","NCT06577337","Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants","A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Single Ascending Doses of M5542 Administered Subcutaneously in Healthy Participants","Inclusion Criteria:\n\n* Participants are overtly healthy, as determined by medical evaluation, by physical examination or laboratory evaluation and no active clinically significant disorder, condition, infection, or disease that would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion at Screening and Day -1\n* Participants have a body weight within the range 50 to 100 kilograms (kg) (inclusive) and body mass index (BMI) within the range 18 to 30.0 kilograms per square meter kg\u002Fm\\^2 (inclusive) at Screening\n* Other protocol defined inclusion criteria could apply\n\nExclusion Criteria:\n\n* History or presence of clinically relevant respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, musculoskeletal, genitourinary, immunological, dermatological, connective tissue, psychiatric and other diseases or disorders, and epilepsy, as determined by medical evaluation at Screening and Day -1\n* Any condition, including findings in the laboratory tests or other screening assessments, that in the opinion of the Investigator constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study's objectives, conduct, or evaluation at Screening and on Day -1\n* History of any malignancy\n* History of chronic or recurrent acute infection or any bacterial, viral, parasitic, or fungal infections within 30 days prior to Screening and at any time between Screening and admission, or hospitalization due to infection within 6 months prior to Screening\n* Immunization with any live vaccine for 12 weeks and subunit or inactivated vaccines for 2 weeks prior to dosing on Day 1. For the herpes zoster vaccine (e.g. Shingrix), if the first dose is administered at least 2 weeks prior to Day 1, the second dose must be administered after the study treatment period has been completed\n* Other protocol defined exclusion criteria could apply",{"count":154,"type":23},49,[26],"The present study in healthy participants will assess the safety, tolerability, immunogenicity, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses (SAD) of subcutaneously administered M5542.",[29],[159],"First-in-Human",{"date":33,"type":36},{"date":162,"type":36},"2024-09-12",{"date":164,"type":23},"2027-03-18",{"name":166,"class":43},"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",{"id":168,"slug":169,"hasResults":12,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":24,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":44},"100647455","phase-1-a-study-of-ly4268989-morf-057-in-healthy-participants-100647455","NCT07707375","A Study of LY4268989 (MORF 057) in Healthy Participants","A Phase 1 Study to Investigate the Pharmacokinetics, Safety and Tolerability of LY4268989 (MORF-057) in Healthy Participants","Inclusion Criteria:\n\n* Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory test, electrocardiograms (ECGs), and vital signs.\n* Have a body mass index (BMI) within the range 18.0 to 32.0 kilogram\u002Fsquare meter (kg\u002Fm²), inclusive, at screening.\n\nExclusion Criteria:\n\n* Have a current or recent acute, active infection. For at least 30 days before screening and up to Day 1, participants must have no symptoms or signs of confirmed or suspected infection and must have completed any appropriate anti-infective treatment.\n* Have presence of significant uncontrolled respiratory, cerebrocardiovascular, cardiovascular, hepatic, renal, gastrointestinal, endocrine, hematologic, neurologic or psychiatric disorders, or abnormal laboratory values at screening that, in the opinion of the sponsor or investigator, pose an unacceptable risk to the participant if participating in the study or of interfering with the interpretation of data.\n* Are immunocompromised to an extent that participation in the study would pose an unacceptable risk to the participant as determined by the investigator.\n* Use or intend to use prescription or nonprescription medication, including dietary supplements, vitamins, herbal supplements, traditional Chinese medicine, alternative medicines, or any medication known to be moderate to strong cytochrome P450 3A4 (CYP3A) inhibitors or inducers, or organic anion transporting polypeptide 1B1 (OATP1B) inhibitors, P-gp inhibitors, or medications that are narrow therapeutic index substrates for breast cancer resistance protein (BCRP) or P-gp within 14 days or 5 half lives, whichever is longer, prior to dosing, until the end of study assessments are complete.","65 Years",{"count":109,"type":23},[26],"The purpose of this study is to identify if two different tablets of LY4268989 (MORF 057) work similarly in healthy participants given different meals.\n\nBlood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.\n\nThere will be 18 inpatient stays at the clinical research unit (CRU). The study will last about 9 weeks.",[29],"2026-08-18",{"date":33,"type":36},{"date":182,"type":36},"2026-07-20",{"date":184,"type":23},"2026-10",{"name":186,"class":43},"Eli Lilly and Company",{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":17,"sex":194,"minAge":19,"maxAge":174,"enrollmentInfo":195,"targetDuration":4,"studyType":24,"phases":197,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":4},"100647305","phase-1-a-study-to-test-how-bi-3034701-is-taken-up-and-processed-by-the-body-in-healthy-men-with-normal-weight-or-overweight-100647305","NCT07708493","A Study to Test How BI 3034701 is Taken up and Processed by the Body in Healthy Men With Normal Weight or Overweight","A Phase I, Open-label, Single-dose, Single-arm Trial to Investigate Metabolism and Pharmacokinetics of BI 3034701 (C-14) Administered to (Otherwise) Healthy Male Volunteers With Normal Body Weight or Overweight","Inclusion criteria:\n\n1. Healthy male trial participant according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure, pulse rate), 12-lead electrocardiogram, and clinical laboratory tests\n2. Age of 18 to 65 years (inclusive)\n3. Body mass index of 23.0 to 34.9 kg\u002Fm2 (inclusive)\n4. Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice and local legislation prior to admission to the trial\n\nExclusion criteria:\n\n1. Any finding in the medical examination (including blood pressure, pulse rate or electrocardiogram) deviating from normal and assessed as clinically relevant by the investigator\n2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 beats per minute (bpm)\n3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance\n4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator\n5. Further exclusion criteria apply.","MALE",{"count":196,"type":23},8,[26],"The main objectives of this trial are:\n\nTo assess the mass balance (total recovery of \\[14C\\]-radioactivity) in urine, faeces, and expired air after a single subcutaneous dose of BI 3034701 (C-14) in healthy male trial participants.",[29],"NOT_YET_RECRUITING",{"date":91,"type":36},{"date":203,"type":23},"2026-08-24",{"date":205,"type":23},"2026-10-14",{"name":207,"class":43},"Boehringer Ingelheim",{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":24,"phases":217,"briefSummary":218,"conditions":219,"keywords":220,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":224,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":44},"100645701","pet-imaging-of-noradrenergic-transmission-in-the-brain-100645701","NCT07686393","PET Imaging of Noradrenergic Transmission in the Brain","* INCLUSION CRITERIA:\n\n  1. Aged 18 years or older.\n  2. Must have undergone a screening assessment under protocol 01-M-0254, The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Participants or 17M0181 Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies.\n  3. Be healthy based on medical history, physical examination, and laboratory testing.\n  4. Able to understand and willingness to provide informed consent.\n  5. Willingness to complete all study procedures including MRI tests.\n  6. Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n  7. Agree to adhere to the lifestyle considerations\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen).\n2. Recent exposure to radiation (i.e., PET from other research) that, when combined with this study, would be above the allowable limits.\n3. Inability to lie flat on camera bed for at least two hours, including claustrophobia and weight greater than the maximum for the scanner (500 lbs).\n4. HIV infection.\n5. Pregnancy or breastfeeding.\n6. Must not have substance use disorder or alcohol use disorder.\n7. Unable to travel to the NIH.\n8. Unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye.\n9. Taking medications reported to have significant binding to alpha-1 adrenoceptors, medications that that alter norepinephrine release, or medications that lower blood pressure including antihypertensives, diuretics, or phosphodiesterase-5(PDE-5) inhibitors (e.g. sildenafil, tadalafil, vardenafil) within five elimination halflives prior to any \\[11C\\]ARMI PET scan.\n10. Known hypersensitivity to quinazoline-class medications (e.g., prazosin), defined as any prior allergic or clinically significant adverse reaction requiring discontinuation or medical evaluation.\n11. Blood donation within 8 weeks (2 months) before study participation, or unwillingness to avoid blood donation for 8 weeks (2 months) after the study.","105 Years",{"count":216,"type":23},40,[26],"Background:\n\nResearchers have developed a new radioactive tracer (11C-ARMI). A tracer is a drug that attaches itself to other chemicals in the body and lights up so that the chemicals can be seen in imaging scans. The new tracer may be able to help them with many diseases, such as Alzheimer s disease and Parkinson s disease. Researchers want to test the new tracer in healthy people.\n\nObjective:\n\nTo test a new tracer (11C-ARMI) during imaging scans of the brain and body in healthy people.\n\nEligibility:\n\nHealthy people aged 18 years and older. They must have been screened under protocols 01-M-0254 or 17M0181.\n\nDesign:\n\nAll participants will have a positron emission tomography (PET)\u002Fcomputed tomography (CT) scan. Before the scan, they will have blood and urine tests and a test of their heart function. The tracer will be given through a tube attached to a needle inserted into a vein in the arm. They will lie on a padded bed that fits inside a doughnut-shaped machine; the machine uses x-rays to create images of the inside of the body.\n\nSome participants will have a PET\u002FCT scan of their whole body. They will need only 1 visit.\n\nSome participants will have a PET\u002FCT scan of only their brain. They will have up to 2 visits. On the second visit, they will have a magnetic resonance imaging (MRI) scan of the brain. For the MRI, they will lie on a table that slides into a cylinder. The MRI uses magnetic fields to create images of the inside of the body.\n\nParticipants will receive a follow-up call to check on their well-being after their PET\u002FCT scans.",[29],[221,222,223,29],"Positron Emission Tomography (PET) Imaging","11C-ARMI","Alpha-1A Adrenoreceptor ( 1A-AR)",{"date":91,"type":36},{"date":226,"type":36},"2026-08-14",{"date":228,"type":23},"2030-02-20",{"name":70,"class":71},{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":24,"phases":238,"briefSummary":239,"conditions":240,"keywords":243,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":246,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":44},"100587886","experiment-3-mixed-vs-blocked-dashboard-paradigm-100587886","NCT06934213","Experiment 3: Mixed vs Blocked; Dashboard Paradigm","Prevalence Effects in Visual Search: Theoretical and Practical Implications (J)","Inclusion Criteria:\n\n• Pass Ishihara color vision test\n\nExclusion Criteria:\n\n• vision less than 20\u002F25 with correction\n\n\\- history of neuromuscular or visual disorders",{"count":109,"type":23},[83],"The goal is to look for qualitative differences in visual search behavior when one search is performed many times in a row compared to when multiple search tasks are intermixed. Four search tasks are tested. The target is the same in every task but the types of distractors change from task to task. In this version, observers get some degree of choice in what they are searching.",[241,29,242],"Vision","Attention",[244,245],"visual search","visual attention",{"date":91,"type":36},{"date":248,"type":36},"2024-06-01",{"date":250,"type":23},"2029-06-30",{"name":252,"class":99},"Brigham and Women's Hospital",{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":24,"phases":261,"briefSummary":262,"conditions":263,"keywords":264,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":267,"leadSponsor":268,"locationsCount":44},"100587846","mixed-vs-blocked-search-four-unique-tasks-100587846","NCT06933693","Mixed Vs Blocked Search: Four Unique Tasks","Prevalence Effects in Visual Search: Theoretical and Practical Implications","Inclusion Criteria:\n\n* Pass Ishihara color vision test\n\nExclusion Criteria:\n\n* vision less than 20\u002F25 with correction\n* history of neuromuscular or visual disorders",{"count":216,"type":23},[83],"The goal is to look for qualitative differences in visual search behavior when one search is performed many times in a row compared to when multiple search tasks are intermixed. Four search tasks are tested. In the Mixed condition, the four tasks are randomly changed from trial to trial. In the Blocked condition, each task is run as a block of 100 trials.",[241,29,242],[244,245],{"date":91,"type":36},{"date":248,"type":36},{"date":250,"type":23},{"name":252,"class":99},{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":24,"phases":278,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":44},"100568427","a-community-health-education-intervention-for-increasing-community-driven-actions-to-reduce-the-cancer-burden-in-western-new-york-100568427","NCT06681077","A Community Health Education Intervention for Increasing Community-driven Actions to Reduce the Cancer Burden in Western New York","I Can Join the Fight Against Cancer: An Intervention to Programmatically Build Grassroots Actions to Reduce the Cancer Burden","Inclusion Criteria:\n\n* Being over 18 years old\n* Able to participate in English\n\nExclusion Criteria:\n\n* Unwilling or unable to follow protocol requirements",{"count":277,"type":23},500,[83],"This clinical trial evaluates a community health education intervention (I CAN) for increasing community-driven actions to reduce the cancer burden in Western New York. Engaging community members is a critical component of designing impactful programs to reduce the cancer burden. Leaders at the national, state, and local levels have all called for more community partnerships and engagement in design of health intervention and policies. The I CAN intervention is a workshop that includes a presentation outlining key concepts related to social network processes and the cancer burden in Western New York, a structured skill-building activity, and then empowering and motivating activities meant to cultivate momentum and excitement for action. This community health education intervention may be able to provide a formalized process for empowering and facilitating community members to take steps to reduce the community cancer burden.",[29],{"date":33,"type":36},{"date":283,"type":36},"2024-11-16",{"date":285,"type":23},"2028-11-15",{"name":287,"class":99},"Roswell Park Cancer Institute",{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":17,"sex":18,"minAge":295,"maxAge":20,"enrollmentInfo":296,"targetDuration":4,"studyType":24,"phases":298,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":4},"100652544","phase-1-a-clinical-trial-of-enlicitide-mk-0616-formulations-in-healthy-participants-mk-0616-044-100652544","NCT07776665","A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044)","A Clinical Study to Evaluate the Relative Bioavailability of Enlicitide Test Formulations Under Fed and Fasted Conditions and Compare to the Reference FMF Tablet in Healthy Adult Participants","Inclusion Criteria:\n\n* Is in good health\n* Has a body-mass index (BMI) between ≥18.0 and ≤32.0 kg\u002Fm\\^2\n\nExclusion Criteria:\n\n* Has history of gastrointestional (GI) disease which might affect food and drug absorption or has had gastric bypass or similar surgery. Examples of GI disease include (but are not limited to) recurrent vomiting, inflammatory bowel disease, chronic intestinal disease accompanied by a disturbance in digestion and absorption, Roemheld's syndrome, and severe hernia\n* Has a history of cancer (malignancy)\n* Has positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV)\n* Is lactose intolerant","19 Years",{"count":297,"type":23},30,[26],"The goal of this trial is to learn what happens to different formulations (types) of enlicitide in a healthy person's body over time. Researchers will compare the amount of enlicitide in a healthy person's body over time when different formulations are given on an empty stomach and after a high-fat meal.",[29],"2026-08-17",{"date":33,"type":36},{"date":304,"type":23},"2026-08-31",{"date":306,"type":23},"2026-12-21",{"name":308,"class":43},"Merck Sharp & Dohme LLC",{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":17,"sex":194,"minAge":19,"maxAge":20,"enrollmentInfo":316,"targetDuration":4,"studyType":24,"phases":318,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":321,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":44},"100652353","phase-1-a-study-in-healthy-men-to-find-out-how-blocking-certain-transport-proteins-affects-the-amount-of-bi-3000202-in-the-blood-100652353","NCT07774325","A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood","The Effects of P-gp Inhibition and OATP Inhibition on the Pharmacokinetics of a Single Oral Dose of BI 3000202 in Healthy Male Trial Participants (an Open-label, Three-period, Two-sequence Crossover Trial, With Period 3 as Fixed Treatment)","Inclusion Criteria:\n\n1. Healthy male trial participant according to the assessment of the investigator, as based on a complete medical history, physical examination, vital signs (Blood pressure, Pulse rate), 12-lead Electrocardiogram, and clinical laboratory tests\n2. Age of 18 to 55 years (inclusive)\n3. Body mass index of 18.5 to 29.9 kg\u002Fm² (inclusive). Additionally, a minimum body weight of at least 60 kg is required\n4. Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice and local legislation prior to admission to the trial\n\nExclusion Criteria:\n\n1. Any finding in the medical examination (including Blood pressure, Pulse rate or Electrocardiogram) deviating from normal and assessed as clinically relevant by the investigator\n2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm\n3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance\n4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator\n5. Further exclusion criteria apply.",{"count":317,"type":23},16,[26],"The main objective of this trial is to investigate the effects of multiple doses of Itraconazole and multiple doses of Ciclosporin on the pharmacokinetics of BI 3000202 in plasma following a single oral dose in healthy male trial participants.",[29],{"date":91,"type":36},{"date":323,"type":23},"2026-09-01",{"date":325,"type":23},"2026-10-26",{"name":207,"class":43},{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":334,"targetDuration":4,"studyType":24,"phases":336,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":340,"startDateStruct":341,"completionDateStruct":342,"leadSponsor":344,"locationsCount":44},"100652003","phase-1-a-study-to-compare-how-2-different-formulations-of-survodutide-are-taken-up-in-the-body-when-given-by-injection-in-healthy-men-and-women-with-and-without-overweight-or-obesity-100652003","NCT07768813","A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity","Bioequivalence of Survodutide (BI 456906) When Administered Via Pre-filled Syringe (Formulation A) and Vial (Formulation B2) in Male and Female Trial Participants Who Are Healthy or Otherwise Healthy But Overweight\u002FObese (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Trial)","Inclusion criteria:\n\n1. Male or female trial participant who is healthy or otherwise healthy with overweight\u002Fobesity according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests\n2. Age of 18 to 55 years (inclusive)\n3. Body mass index (BMI) of 22.0 to 39.9 kg\u002Fm\\^2 (inclusive)\n4. Signed and dated written informed consent in accordance with international council for harmonisation - good clinical practice (ICH-GCP) and local legislation prior to admission to the trial\n5. Further inclusion criteria apply.\n\nExclusion criteria:\n\n1. Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator\n2. Repeated measurement of systolic BP outside the range of 90 to 140 mmHg, diastolic BP outside the range of 50 to 90 mmHg, or PR outside the range of 45 to 90 bpm\n3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance\n4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator\n5. Further exclusion criteria apply.",{"count":335,"type":23},44,[26],"The main objective of this trial is to establish the bioequivalence of survodutide in a pre-filled syringe (reference product \\[formulation A\\]) and in a vial (test product \\[formulation B2\\]) in male and female trial participants who are healthy or otherwise healthy with overweight\u002Fobesity, following subcutaneous administration.",[29,339],"Obesity",{"date":179,"type":36},{"date":323,"type":23},{"date":343,"type":23},"2026-12-22",{"name":207,"class":43},{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":352,"targetDuration":4,"studyType":24,"phases":354,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":357,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":44},"100648979","phase-1-a-study-in-healthy-people-to-compare-two-tablet-formulations-of-pramipexole-100648979","NCT07727785","A Study in Healthy People to Compare Two Tablet Formulations of Pramipexole","Bioequivalence of Two Pramipexole Tablets Following Oral Administration in Healthy Participants (an Open-label, Randomised, Multiple-dose, Two-way Crossover Trial)","Inclusion criteria:\n\n1. Healthy male or female trial participant according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), and 12-lead electrocardiogram (ECG)\n2. Age of 18 to 55 years (inclusive)\n3. Body mass index (BMI) of 18.5 to 29.9 kg\u002Fm\\^2 (inclusive)\n4. Signed and dated written informed consent in accordance with international council for harmonisation - good clinical practice (ICH-GCP) and local legislation prior to admission to the trial\n5. Further inclusion criteria apply.\n\nExclusion criteria:\n\n1. Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator\n2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimeters of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 beats per minute (bpm)\n3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance\n4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator\n5. Further exclusion criteria apply.",{"count":353,"type":23},24,[26],"The goal of this study is to find out whether pramipexole tablets made at two different production sites are handled in the same way by the body.",[29],{"date":179,"type":36},{"date":359,"type":36},"2026-08-05",{"date":361,"type":23},"2026-09-28",{"name":207,"class":43},{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":370,"targetDuration":4,"studyType":24,"phases":372,"briefSummary":373,"conditions":374,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":377,"leadSponsor":379,"locationsCount":44},"100644870","phase-1-a-clinical-trial-of-mk-1403-in-healthy-participants-mk-1403-007-100644870","NCT07677163","A Clinical Trial of MK-1403 in Healthy Participants (MK-1403-007)","A Clinical Study to Evaluate the Relative Bioavailability of MK-1403 Formulations Administered to Healthy Adult Participants","Inclusion Criteria:\n\n* Is in good health\n* Has a body mass index (BMI) ≥ 18 and ≤ 32 kg\u002Fm\\^2\n\nExclusion Criteria:\n\n* Has history of cancer (malignancy)\n* Has a history of significant multiple and\u002For severe allergies",{"count":371,"type":23},15,[26],"The purpose of this trial is to learn about a trial medicine called MK-1403. Researchers designed MK-1403 to treat a type of heart and blood vessel disease called atherosclerotic cardiovascular disease (ASCVD).\n\nBefore giving a trial medicine to people with a health condition, researchers first do clinical trials in healthy people. This trial will help researchers learn about the safety of MK-1403 and if participants tolerate it. Tolerate means participants receive the trial medicine and they do not need to stop taking it due to health problems. The trial will also measure what happens to MK 1403 in a healthy person's body over time.",[29],{"date":91,"type":36},{"date":226,"type":36},{"date":378,"type":23},"2026-09-22",{"name":308,"class":43},{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":388,"enrollmentInfo":389,"targetDuration":4,"studyType":391,"phases":4,"briefSummary":392,"conditions":393,"keywords":397,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":44},"100429529","development-of-a-non-invasive-screening-tool-to-predict-metabolic-dysfunction-associated-steatotic-liver-disease-100429529","NCT04873258","Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease","Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Volunteers on Clinical Trials Utilising Machine-learning and Bioimpedance Vector Analysis","MASLD","Inclusion Criteria:\n\n1. Male or female volunteers aged ≥18 to ≤80 years at the date of signing the informed consent.\n2. Willingness and ability to provide written, personally signed, and dated informed consent, in accordance with the latest ICH Good Clinical Practice (GCP) Guidelines and applicable regulations.\n3. An understanding, ability and willingness to fully comply with project procedures and restrictions.\n\nFor PART B only:\n\n1\\. With a known history of MASLD as evidenced either of:\n\n1. GP diagnosis on HCF\n2. Documented Fibroscan or liver US demonstrating MASLD\n\nExclusion Criteria:\n\n1. Known alcoholic liver disease, history of cirrhosis of any other cause (metabolic, viral hepatitis or other)\n2. Any other significant previous liver pathology (liver malignancy, portal hypertension, infiltrative liver disease)\n3. Alcohol consumption \\>30 units per week\n4. An Implanted cardiac devices","80 Years",{"count":390,"type":23},2000,"OBSERVATIONAL","A generic screening study to establish structural and\u002For functional baselines of specific organs.",[29,394,386,395,396],"Fatty Liver","MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Obesity and Obesity-related Medical Conditions",[398,386],"Fatty liver",{"date":91,"type":36},{"date":401,"type":36},"2019-09-27",{"date":403,"type":23},"2027-12-31",{"name":405,"class":43},"Richmond Research Institute",{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":412,"enrollmentInfo":413,"targetDuration":4,"studyType":24,"phases":414,"briefSummary":415,"conditions":416,"keywords":417,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":44},"100583275","phase-1-assessment-of-11c-jmj-129-for-imaging-pde4d-in-brain-and-whole-body-of-healthy-volunteers-100583275","NCT06874205","Assessment of 11C-JMJ-129 for Imaging PDE4D in Brain and Whole Body of Healthy Volunteers","* INCLUSION CRITERIA:\n* Aged 18 years or older.\n* Participants must have undergone a screening assessment under protocol 01-M-0254, \"The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Participants.\"\n* Healthy based on medical history, physical examination, and laboratory testing.\n* Able to provide informed consent.\n* Willing and able to complete all study procedures including MRI tests.\n* Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n* Agree to adhere to the lifestyle considerations\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen).\n* Any current Axis I diagnosis.\n* History of neurologic illness or injury with the potential to affect study data interpretation.\n* History of seizures, other than in childhood and related to fever.\n* Recent exposure to radiation (i.e., PET from other research) which when combined with this study would be above the allowable limits.\n* Inability to lie flat on camera bed for at least two hours, including claustrophobia and weight greater than the maximum for the scanner (500 lbs).\n* HIV Infection.\n* Pregnancy or breast feeding.\n* Participants must not have substance use disorder or alcohol use disorder.\n* Unable to travel to the NIH.\n* Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye.\n\nAdditional exclusions for participants receiving disulfiram:\n\nParticipants will be excluded if any of the following apply:\n\n1. Current use of, or use within the past 14 days, of metronidazole or paraldehyde.\n2. Consumption of alcohol or alcohol-containing products within 24 hours prior to disulfiram administration, or inability\u002Funwillingness to abstain from alcohol containing products for 14 days after administration.\n3. History or presence of severe myocardial disease or coronary occlusion. Current or past history of psychotic disorders.\n4. Known hypersensitivity to disulfiram or other thiuram derivatives.","101 Years",{"count":216,"type":23},[26],"Background:\n\nPDE4D is a protein in the body that plays a role in thinking and depression. This protein may play a major role in disorders such as Alzheimer disease or major depressive disorder. To learn more about these disorders, researchers want to be able to detect levels of PDE4D in the brain. 11C-JMJ-129 is a new radiotracer (a radioactive substance that highlights parts of the body during imaging scans) that was developed to attach only to PDE4D. However, early human studies showed that the tracer may break down in the body and create byproducts that interfere with the brain signal, making the results harder to interpret. This study will test whether a medication called disulfiram can improve PET imaging with 11C-JMJ-129. Disulfiram blocks an enzyme in the body that may be responsible for breaking down the tracer. By reducing this breakdown, the study aims to improve the quality and accuracy of brain images. The results may help researchers better measure PDE4D in the brain and support future studies of brain disorders.\n\nObjective:\n\nTo test the new radiotracer 11C-JMJ-129, with and\u002For without disulfiram pretreatment during imaging scans in healthy volunteers.\n\nEligibility:\n\nHealthy people aged 18 years and older who had a screening assessment under protocol 01-M-0254.\n\nDesign:\n\nParticipants will have 1 to 4 clinic visits.\n\nParticipants will be screened. They will have a physical exam. They will have blood tests and a test of their heart function.\n\nParticipants will undergo 1 or more of these scans:\n\nA positron emission tomography (PET) scan of the whole body. The radiotracer will be injected through a tube placed in a vein in the arm. Participants will lie on a table while a donut-shaped machine passes over them. Blood will be drawn from the arm during this scan.\n\nIn Phase 5, disulfiram (500 mg orally) will be administered approximately 20 hours before the post-disulfiram PET scan\n\nA magnetic resonance imaging (MRI) scan of the brain. Participants will lie on a table that slides into a tube.\n\nA PET scan of the brain. These participants will be injected with the radiotracer. They will lie on a table with their head in the scanner.\n\nParticipants will be called within 3 days after each PET scan for a check on their health.",[29],[418,63],"11C-JMJ-129","2026-08-15",{"date":179,"type":36},{"date":422,"type":36},"2025-04-11",{"date":424,"type":23},"2029-02-05",{"name":70,"class":71},{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":388,"enrollmentInfo":434,"targetDuration":4,"studyType":24,"phases":436,"briefSummary":438,"conditions":439,"keywords":443,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":44},"100484326","phase-1-sv2a--tspo-pet-imaging-measures-to-reveal-mechanisms-of-hiv-neuropathogenesis-during-antiretroviral-therapy-100484326","NCT05586581","SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy","PET Imaging of Synaptic Density Combined With Neuroimmunologic Measures to Reveal Mechanisms of HIV Neuropathogenesis During ART","ART","PLWH Inclusion Criteria:\n\n* Voluntary, written, informed consent (signed and dated)\n* For females, a negative urine or serum pregnancy (HCG) test at screening and on each scan day before initiation of any scan procedures.\n* HIV infection on cART with documented viral suppression for at least one year. Plasma viral suppression will be defined as no more than one viral load\n* Test above 20 HIV RNA cps\u002FmL in the year prior to screening and no HIV RNA tests above 200 cps\u002FmL in the same span.\n* Willingness to participate in MRI, PET, phlebotomy, and Neuropsychological Testing (NPT) Assessments \\& Surveys.\n\nPLWH Exclusion Criteria:\n\n* Active substance dependence (e.g., heroin, alcohol, cocaine, sedative hypnotics, methamphetamine) as determined by the standardized Behavioral Assessments.\n* A history of significant non-HIV related neurological illness (e.g., cerebrovascular, seizures, traumatic brain injury).\n* Medical contraindications to the administration of radioactivity (e.g., prior radiation exposure within the past year from research, or from workplace exposure, that in combination with the planned scans would exceed the FDA limit for annual radiation exposure).\n* Medical contraindications to participation in a magnetic resonance imaging procedure (e.g., ferromagnetic implants\u002Fforeign bodies, claustrophobia, cardiac pacemaker, prosthetic valve, otologic implant, etc.).\n* History of a bleeding disorder, low platelet count, or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto).\n\nHIV - Inclusion Criteria:\n\n* Voluntary, written, informed consent (signed and dated)\n* For females, a negative urine or serum pregnancy (HCG) test at screening and on each scan day before initiation of any scan procedures.\n* Willingness to participate in phlebotomy, NPT Assessments \\& Surveys, MRI, and PET.\n* Physically healthy by medical history, physical, neurological, and laboratory examinations, as judged by the principal investigator.\n* Have a negative test for HIV on file within the last three months or willing to have an HIV test in the current study.\n\nHIV- Exclusion Criteria:\n\n* Active substance dependence (e.g., heroin, alcohol, cocaine, sedative hypnotics, methamphetamine) as determined by the standardized Behavioral Assessments.\n* A history of significant neurological illness (e.g., cerebrovascular, seizures, traumatic brain injury).\n* Medical contraindications to the administration of radioactivity (e.g., prior radiation exposure within the past year, from research, or from workplace exposure, that in combination with the planned scans would exceed the FDA limit for annual radiation exposure)\n* Medical contraindications to participation in a magnetic resonance imaging procedure (e.g., ferromagnetic implants\u002Fforeign bodies, claustrophobia, cardiac pacemaker, prosthetic valve, otologic implant, etc.\n* History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto",{"count":435,"type":23},70,[26,437],"PHASE2","The purpose of this study is to longitudinally characterize and evaluate changes in synaptic density in the brain using novel positron-emission tomography (PET) scans; magnetic resonance imaging (MRI), and clinical laboratory markers associated with HIV-related injury in the central nervous system. This study will test hypotheses relating to the presence and mechanisms of aberrant brain structure at the synaptic level in living humans with virologically controlled HIV on antiretroviral therapy. To evaluate associations between PET imaging radiotracers \\[11C\\]UCB-J, a ligand for presynaptic vesicle protein 2A (SV2A), a vesicle membrane protein expressed in synapses, and PET \\[11C\\]PBR28 a measure of microglia function in the brain, the Yale PET center has developed an advanced approach of combining multiple distinct ligands in coordinated same-day PET imaging. Additionally, the study will evaluate the associations of this novel synaptic density marker with well-established clinical measures of neurocognitive performance and laboratory measures of blood and cerebrospinal fluid (CSF).",[440,441,442,29],"HIV Associated Neurocognitive Disorder","HIV Dementia","HIV Encephalitis",[444,445,446,447,448,449,450,451,452,453,454,455,456,457,458],"Human immunodeficiency virus","Positron-Emission Tomography Imaging","Magnetic Resonance Imaging","Cerebrospinal Fluid","SV2A PET","TSPO PET","Neuro-immune dysfunction","Neuro-Inflammation","Biomarkers of inflammation","Neuronal Injury","Neurocognitive functioning","Hippocampus","Microglia","Neuropathogenesis","antiretroviral therapy",{"date":179,"type":36},{"date":461,"type":36},"2023-05-17",{"date":463,"type":23},"2030-12",{"name":465,"class":99},"Yale University",{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":412,"enrollmentInfo":472,"targetDuration":4,"studyType":24,"phases":473,"briefSummary":474,"conditions":475,"keywords":476,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":478,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":44},"100642123","phase-1-evaluation-of-11cztp-1-to-image-pde4b-100642123","NCT07625345","Evaluation of [11C]ZTP-1 to Image PDE4B","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet the following criteria:\n\n* Aged 18 years or older.\n* Must have undergone a screening assessment under protocol 01M-0254, \"The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Participants or protocol 17M0181 Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies.\"\n* Be healthy based on medical history, physical examination, and laboratory testing.\n* Able to provide informed consent.\n* Willingness to complete all study procedures including MRI tests.\n* Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n* Agree to adhere to the lifestyle considerations\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen).\n* History of neurologic illness or injury with the potential to affect study data interpretation.\n* History of seizures, other than in childhood and related to fever.\n* Recent exposure to radiation (i.e., PET from other research) that, when combined with this study, would be above the allowable limits.\n* Inability to lie flat on camera bed for at least two hours, including claustrophobia and weight greater than the maximum for the scanner (500 lbs).\n* HIV infection.\n* Pregnancy or breastfeeding.\n* Must not have substance use disorder or alcohol use disorder.\n* Unable to travel to the NIH.\n* Unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye.\n* Known hypersensitivity to phosphodiesterase-4 (PDE-4) inhibitors (e.g. apremilast, roflumilast, nerandomilast, crisborole).\n* Taking CYP3A4 inhibitors (e.g. grapefruit juice, clarithromycin, erythromycin, ritonavir); CYP3A4 inducers (e.g. phenobarbital St. John's Wort, rifampicin) or oral contraceptives containing gestodene and ethinyl estradiol.\n\nEXCLUSION OF CHILDREN:\n\nInclusion of children is not appropriate, because this protocol has more than minimal risk from radiation exposure without the possibility of direct benefit.\n\nEXCLUSION OF PREGNANT OR BREASTFEEDING WOMEN:\n\nPregnant women will be excluded because this protocol involves exposure to ionizing radiation. Lactating women will be excluded because radioisotopes may be excreted in milk. We will perform a pregnancy test at screening and prior to all procedures to ensure participants are not pregnant. The test must be negative in order to continue on the study. In addition to completing a negative urine pregnancy test, on the day of PET scanning prior to PET scan procedures, participants of childbearing potential will undergo a clinical pregnancy screening interview with a licensed independent practitioner to confirm lack of pregnancy.\n\nEXCLUSION OF PARTICIPANTS WHO ARE HIV POSITIVE:\n\nPersons with HIV infection are excluded because HIV infection itself may change cAMP signaling.",{"count":216,"type":23},[26],"Background:\n\nPDE4B is a protein in cells that helps turn off certain chemical signals after they ve done their job. It controls inflammation, immune responses, and some brain signaling. Measuring PDE4B levels in the body can help doctors manage a disease or know if a treatment is working. Researchers want to find out if a new tracer (a radioactive substance injected during imaging scans) can help them measure PDE4B in people more effectively.\n\nObjective:\n\nTo test a new tracer (\\[11C\\]ZTP-1) during imaging scans of the brain and body in healthy people.\n\nEligibility:\n\nHealthy people aged 18 and older. They must have been screened under protocols 01M-0254 or 17M0181.\n\nDesign:\n\nParticipants will have either 1 or 2 clinic visits.\n\nDuring their first visit, all participants will have a positron emission tomography (PET)\u002Fcomputed tomography (CT) scan. Prior to the scan, they will have blood and urine tests and a test of their heart function. The study tracer will be given through a tube attached to a needle inserted into a vein in the arm. They will lie on a padded bed that fits inside a doughnut-shaped machine; the machine uses x-rays to create images of the inside of the body.\n\nSome participants will have a PET\u002FCT scan of their whole body. They will need only 1 visit. The visit will last up to about 8 hours.\n\nSome participants will have a PET\u002FCT scan of only their brain. They will also have a magnetic resonance imaging (MRI) scan of the brain. They may need to return for a second visit for the MRI scan.\n\nParticipants will receive a follow-up call to check on their well-being after their PET\u002FCT scans.",[29],[63,477],"11C-ZTP-1",{"date":301,"type":36},{"date":480,"type":36},"2026-07-01",{"date":482,"type":23},"2030-10-03",{"name":70,"class":71},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":17,"sex":18,"minAge":491,"maxAge":492,"enrollmentInfo":493,"targetDuration":4,"studyType":24,"phases":495,"briefSummary":496,"conditions":497,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":498,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":504},"100593980","phase-3-a-study-to-evaluate-v181-dengue-vaccine-in-healthy-participants-2-to-17-years-of-age-v181-005mobilize-1-100593980","NCT07013487","A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005\u002FMOBILIZE-1)","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age","The key Inclusion Criteria include but are not limited to:\n\n* Is generally healthy based on medical history and physical examination.\n\nThe key Exclusion Criteria include but are not limited to:\n\n* Has a known or suspected impairment of immunological function.\n* Has a history of congenital or acquired immunodeficiency.\n* Has a documented human immunodeficiency virus (HIV) infection or is breastfeeding from a mother with documented HIV infection.\n* Has a documented history of hepatitis B or C infection.\n* Has a bleeding disorder contraindicating subcutaneous vaccination or repeated venipuncture.\n* Has a serious or progressive disease, including but not limited to cancer, uncontrolled diabetes, severe cardiac, renal or hepatic insufficiency, or systemic autoimmune or neurologic disorders.\n* Has a known neurologic or cognitive behavioral disorder, including encephalitis\u002Fmyelitis, acute disseminating encephalomyelitis, pervasive development disorder, and related disorders.\n* Previous receipt of a dengue vaccine or plans to receive any dengue vaccine (investigational or approved) for the duration of the study (other than the study vaccine).\n* Received systemic corticosteroids \\\u003C30 days before receipt of study intervention or is expected to require systemic corticosteroids ≤28 days after receipt of study intervention.\n* Has received a blood transfusion or blood products, including immunoglobulins, ≤6 months before receipt of study intervention or plans to receive a blood transfusion or blood products (including immunoglobulins) ≤28 days after receipt of study intervention.\n* Has received immunosuppressive therapies, including chemotherapeutic agents used to treat cancer or other conditions, treatments associated with organ or bone marrow transplantation, or autoimmune disease, ≤6 months before receipt of study intervention or plans to receive immunosuppressive therapies ≤28 days after receipt of study intervention.","2 Years","17 Years",{"count":494,"type":23},12000,[133],"The purpose of this study is to demonstrate that V181 is safe and well tolerated, elicits an immune response, and reduces the frequency of virologically confirmed dengue (VCD) of any severity, due to any of the 4 dengue serotypes, regardless of dengue serostatus at baseline in children 2 to 17 years of age.",[29],{"date":179,"type":36},{"date":500,"type":36},"2025-06-11",{"date":502,"type":23},"2031-10-24",{"name":308,"class":43},36,{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":512,"targetDuration":4,"studyType":24,"phases":514,"briefSummary":515,"conditions":516,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":517,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":44},"100470084","phase-1-glutamatergic-mechanisms-aim2-100470084","NCT05401227","Glutamatergic Mechanisms: Aim2","Glutamatergic Mechanisms of Psychosis and Target Engagement: Aim2","Inclusion Criteria:\n\n1. Age between 18-55 at screen\n2. Medically healthy, as assessed by study physician at screen\n3. Capable of understanding the study procedures and able to provide informed consent\n4. Eligible men and women must agree to use a reliable method of birth control (See section 5.3) during the study. Women who are post-menopausal or otherwise not of childbearing potential are also eligible.\n5. Willing and reliable to participate in XT or placebo phase as an outpatient and\u002For agreeable to participate as an inpatient.\n\nExclusion Criteria:\n\n1. Current or past Axis I psychiatric history (including Substance Use Disorder\u002FAlcohol Use Disorder, with the exception of nicotine use disorder) as assessed at screen\n2. Positive urine toxicology or alcohol at screen\n3. History of recreational ketamine use, recreational PCP use, or an adverse reaction to ketamine. Participants who have participated in prior research ketamine studies will be eligible. Participants can have infusions not more frequently than biweekly, and not more than 1\u002Fmonth on average, therefore participants entering the study will need to wait one month if they had a single infusion and 6 weeks if they have had two closely spaced infusions.\n4. History of first-degree relative with schizophrenia\n5. Pregnancy or breast-feeding. This exclusion criterion applies only to females of child-bearing potential (not surgically sterilized and between menarche and 1 year postmenopausal). Must test negative for pregnancy at the time of screening based on a serum pregnancy test.\n6. History of violence, including any history of using a gun, knife, or other weapon with intent to harm someone, as well as more than one physical fight without a weapon after the age of 18 years old (not including fights that happen during sports competition).\n7. Presence or positive history of significant medical illness at screen, including:\n\n   * Contraindications to XT (urinary retention, moderate or severe hepatic impairment, gastric retention, untreated narrow-angle glaucoma, hypernasality)\n   * renal problems (GFR\\\u003C60)\n   * high blood pressure (defined as supine systolic blood pressure (SBP) \\> 140 or supine diastolic blood pressure (DBP) \\> 90)\n   * low blood pressure (defined as supine SBP \\\u003C 100, DBP \\\u003C 60)\n   * abnormal orthostatic blood pressure (change in mean arterial pressure \\[1\u002F3 systolic + 2\u002F3 diastolic\\] of \\> 20% between supine and standing blood pressures)\n   * clinically significant cardiac illness, as determined by the site physician\n   * clinically significant abnormal screening labs, as determined by the site physician\n8. Participants with suicidal ideation with intent or plan (indicated by affirmative answers to items 4 or 5 of the Suicidal Ideation section of the baseline C-SSRS) in the 6 months prior to screening or participants who represent a significant risk of suicide in the opinion of the investigator.\n9. Presence or positive history of neurological illness, including seizures, mental retardation or any other disease\u002Fprocedure\u002Faccident\u002Fintervention associated with significant injury to or malfunction of the central nervous system (CNS), or history of significant head injury.\n10. Any material in the body that is a contraindication for MRI procedures\n11. Currently taking any psychotropic medication, including antidepressant medications, benzodiazepines, antipsychotic medications, mood stabilizers, anti-epileptic medications, and stimulants. We will exclude any participant who requires treatment with any psychotropic medication from one of these classes.",{"count":513,"type":23},120,[26],"In the present study, 120 healthy volunteers (HV) will be randomized to one of three ketamine-induced pharmacoBOLD (phBOLD) arms: low, medium, and high. Within each ketamine arm, participants will be randomized to 4 days of \"study drug\" \\[TS-134 (1st 20 participants) or XT (remaining 100 participants)\\] or placebo in a 5:3 ratio (25 study drug:15 placebo per arm).\n\nDuring the study, each participant will undergo a Screening Period (up to 31 days), a 4-day Treatment Period, and a total of two phBOLD sessions: a first session at Baseline and a second session on Day 4 of the Treatment Period, conducted at least 7 days apart, and a follow up visit.",[29],{"date":301,"type":36},{"date":519,"type":36},"2022-10-15",{"date":521,"type":23},"2029-08",{"name":523,"class":99},"New York State Psychiatric Institute",{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":530,"eligibilityCriteria":531,"healthyVolunteers":17,"sex":18,"minAge":532,"maxAge":174,"enrollmentInfo":533,"targetDuration":4,"studyType":391,"phases":4,"briefSummary":535,"conditions":536,"keywords":538,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":44},"100593766","digital-measures-for-clinical-trial-endpoints-in-huntingtons-disease-100593766","NCT07010705","Digital Measures for Clinical Trial Endpoints in Huntington's Disease","Digital Measures for Clinical Trial Endpoints in Huntington's Disease (MEND-HD)","MEND-HD","Inclusion Criteria:\n\nInclusion Criteria for participants with adult-onset HD:\n\n* Age of 25-65 years.\n* Genetically confirmed HD with CAG \\>= 40 (HD-ISS Stage 2 or mild\u002Fmoderate Stage 3)\n* English speaking.\n\nInclusion Criteria for control participants:\n\n* Age of 25-65 years.\n* English speaking.\n\nInclusion Criteria for support persons:\n\n* Self-identified support person or family member of the enrolled participants with HD.\n* 18 years or older\n* English speaking.\n\nExclusion Criteria:\n\n* Diagnosis of juvenile-onset HD.\n* History of co-morbid neurological disease or disorders such as stroke, multiple sclerosis, or moderate to severe\n* Traumatic Brain Injury.\n* Use of an assistive device for ambulation.\n* Montreal Cognitive Assessment (MoCA) score of 18 or lower\n* Acute or chronic medical conditions that significantly impact gait or mobility in the opinion of the investigator, e.g. ankle sprain or fracture, or any orthopedic,\n* cardiovascular or psychiatric disease.\n* Pregnancy\n* Cannot be enrolled into a blinded intervention trial at Baseline","25 Years",{"count":534,"type":23},100,"MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners\u002Fsupport persons.\n\nParticipants will take part in four virtual visits with study investigators to answer survey questions on movement and cognition, perform in-home movement assessments, and take part in an interview regarding the meaningfulness of gait and chorea in their daily lives.\n\nParticipant and care partner interviews will be used for symptom mapping and qualitative data analysis to assess the relevance and impact of the targeted symptoms on the participant's daily life.\n\nThe study may be extended to 3 years to include yearly visits.",[537,29],"Huntington Disease",[537],"2026-08-13",{"date":301,"type":36},{"date":542,"type":36},"2025-06-20",{"date":544,"type":23},"2027-11-30",{"name":546,"class":99},"University of Rochester",{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":17,"sex":18,"minAge":554,"maxAge":174,"enrollmentInfo":555,"targetDuration":4,"studyType":24,"phases":557,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":567},"100651958","phase-1-a-study-of-ly4226695-in-healthy-participants-100651958","NCT07767487","A Study of LY4226695 in Healthy Participants","A Single-ascending and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY4226695 in Healthy Participants","Inclusion Criteria:\n\n* Have a screening body mass index (BMI) in the range of 18.5 to 35 kilograms per square meter (kg\u002Fm²), inclusive, with no significant weight gain or loss in the past 3 months prior to screening.\n* Individuals assigned male at birth must agree to adhere to contraception restrictions and individuals assigned female at birth must not be of childbearing potential.\n* Part B Chinese participants:\n\n  * To qualify as a Chinese participant for the purpose of this study, all the participants' biological grandparents must be Chinese and born in China.\n* Part C Japanese participants:\n\n  * To qualify as a Japanese participant for the purpose of this study, all the participants' biological grandparents must be Japanese and born in Japan.\n\nExclusion Criteria:\n\n* Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders.\n* Have known or ongoing psychiatric disorders.\n* Have a history of deep vein thrombosis of the leg or repeated episodes of deep leg vein thrombosis in first-degree relatives (parents, siblings, or children).\n* Have a history of fracture within 6 months prior to screening.\n* Have a history of fainting.\n* Regularly use known drugs of abuse or with positive drug results.\n* Have alcohol intake that exceeds recommended average weekly alcohol consumption limits per local regulation.","22 Years",{"count":556,"type":23},148,[26],"The main purpose of this study is to assess how well LY4226695 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant in Parts A \\& D, the study will last about 64 days and will include a stay in the Clinical Research Unit (CRU) lasting at most 7 days. For each participant in Parts B \\& C, the study will last about 92 days and will include 5 stays in the CRU with each visit lasting at most 7 days.",[29],"2026-08-12",{"date":301,"type":36},{"date":563,"type":23},"2026-08",{"date":565,"type":23},"2027-07",{"name":186,"class":43},2]